MED Medifast Inc

  1. Stocks
  2. Consumer Cyclical
  3. NYSE: MED

Price (delayed)

$33.57

Market cap

$365.77M

P/E Ratio

3.68

Dividend/share

$6.59

EPS

$9.13

Enterprise value

$293.34M

Medifast is the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers scientifically developed products, clinically proven plans and the support of Coaches and a ...

Highlights
The company's quick ratio has surged by 163% YoY and by 14% QoQ
The price to earnings (P/E) is 74% less than the 5-year quarterly average of 14.3 and 50% less than the last 4 quarters average of 7.4
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter
Medifast's gross profit has decreased by 32% YoY and by 11% from the previous quarter
Sector: Consumer Cyclical
Industry: Personal Services
Website: http://www.medifast1.com
Peers: WTW ABEO

Key stats

What are the main financial stats of MED
Market
Shares outstanding
10.9M
Market cap
$365.77M
Enterprise value
$293.34M
Valuations
Price to earnings (P/E)
3.68
Price to book (P/B)
1.81
Price to sales (P/S)
0.34
EV/EBIT
2.32
EV/EBITDA
2.04
EV/Sales
0.27
Earnings
Revenue
$1.07B
EBIT
$126.31M
EBITDA
$144.02M
Free cash flow
$141.17M
Per share
EPS
$9.13
Free cash flow per share
$12.97
Book value per share
$18.5
Revenue per share
$98.5
TBVPS
$28.47
Balance sheet
Total assets
$309.91M
Total liabilities
$108.43M
Debt
$22.01M
Equity
$201.48M
Working capital
$131.73M
Liquidity
Debt to equity
0.11
Current ratio
2.43
Quick ratio
1.63
Net debt/EBITDA
-0.5
Margins
EBITDA margin
13.4%
Gross margin
72.4%
Net margin
9.3%
Operating margin
11.8%
Efficiency
Return on assets
31.3%
Return on equity
53%
Return on invested capital
116.1%
Return on capital employed
58%
Return on sales
11.8%
Dividend
Dividend yield
19.63%
DPS
$6.59
Payout ratio
72.2%

MED stock price

How has the Medifast stock price performed over time
Intraday
0.45%
1 week
5.3%
1 month
-3.26%
1 year
-64.33%
YTD
-50.06%
QTD
-12.4%

Financial performance

How have Medifast's revenue and profit performed over time
Revenue
$1.07B
Gross profit
$775.85M
Operating income
$126.4M
Net income
$99.42M
Gross margin
72.4%
Net margin
9.3%
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter
Medifast's gross profit has decreased by 32% YoY and by 11% from the previous quarter
The operating income fell by 32% YoY and by 16% QoQ
MED's net income is down by 31% YoY and by 17% QoQ

Growth

What is Medifast's growth rate over time

Valuation

What is Medifast stock price valuation
MED P/E details
P/E
3.68
P/B
1.81
P/S
0.34
EV/EBIT
2.32
EV/EBITDA
2.04
EV/Sales
0.27
The price to earnings (P/E) is 74% less than the 5-year quarterly average of 14.3 and 50% less than the last 4 quarters average of 7.4
The EPS has declined by 29% year-on-year and by 17% since the previous quarter
MED's P/B is 83% below its 5-year quarterly average of 10.5 and 64% below its last 4 quarters average of 5.0
The equity has grown by 30% YoY and by 4.4% from the previous quarter
The P/S is 77% lower than the 5-year quarterly average of 1.5 and 51% lower than the last 4 quarters average of 0.7
MED's revenue is down by 33% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Medifast business performance
MED's ROE is down by 40% YoY and by 22% QoQ
The ROA has decreased by 23% YoY and by 17% from the previous quarter
The return on invested capital has declined by 22% since the previous quarter and by 14% year-on-year
The return on sales has declined by 4.1% since the previous quarter

Dividends

What is MED's dividend history
Dividend details
DPS
$6.59
Dividend yield
19.63%
Payout ratio
72.2%
Recent dividends

Financial health

How did Medifast financials performed over time
The total assets is 186% greater than the total liabilities
The company's quick ratio has surged by 163% YoY and by 14% QoQ
MED's current ratio has soared by 54% year-on-year and by 19% since the previous quarter
Medifast's debt is 89% less than its equity
Medifast's debt to equity has decreased by 35% YoY and by 8% from the previous quarter
The equity has grown by 30% YoY and by 4.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.